•
Dec 31, 2021

Corcept Therapeutics Q4 2021 Earnings Report

Reported financial results for Q4 and full year 2021 and provided a corporate update.

Key Takeaways

Corcept Therapeutics reported Q4 2021 revenue of $98.8 million, compared to $85.7 million in Q4 2020. GAAP net income was $32.1 million, compared to $26.0 million in the same quarter of the previous year. The company anticipates 2022 revenue of $400 – $430 million.

Fourth quarter revenue was $98.8 million, compared to $85.7 million in fourth quarter 2020.

2021 revenue reached $366.0 million, compared to $353.9 million in 2020.

The company provided 2022 revenue guidance of $400 – $430 million.

Fourth quarter GAAP net income amounted to $32.1 million, compared to $26.0 million in fourth quarter 2020.

Total Revenue
$98.8M
Previous year: $85.7M
+15.3%
EPS
$0.35
Previous year: $0.27
+29.6%
Gross Profit
$97.5M
Previous year: $84.5M
+15.4%
Cash and Equivalents
$336M
Previous year: $477M
-29.6%
Free Cash Flow
$49.4M
Previous year: $34.6M
+42.5%
Total Assets
$424M
Previous year: $572M
-25.9%

Corcept Therapeutics

Corcept Therapeutics